It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The alpha-2,8-linked form of the polysaccharide polysialic acid (PSA) has widespread implications in physiological and pathological processes, ranging from neurological development to disease progression. Though the high electronegativity and excluded volume of PSA often promotes interference of biomolecular interactions, PSA-binding ligands have important implications for both biological processes and biotechnological applications. As such, the design, identification, and characterisation of novel ligands towards PSA is critical for expanding knowledge of PSA interactions and achieving selective glycan targeting. Here, we report on a rational approach for the identification of alpha-2,8-PSA-binding peptides, involving design from the endogenous ligand Siglec-11 and multi-platform characterisation of peptide binding. Microarray-based examination of peptides revealed charge and sequence characteristics influencing peptide affinity to PSA, and carbohydrate–peptide binding was further quantified with a novel fluorescence anisotropy assay. PSA-binding peptides exhibited specific binding to polymeric SA, as well as different degrees of selective binding in various conditions, including competition with PSA of alternating 2,8/9-linkages and screening with PSA-expressing cells. A computational study of Siglec-11 and Siglec-11-derived peptides offered synergistic insight into ligand binding. These results demonstrate the potential of PSA-binding peptides for selective targeting and highlight the importance of the approaches described herein for the study of carbohydrate interactions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Rensselaer Polytechnic Institute, Department of Biological Sciences, Troy, USA (GRID:grid.33647.35) (ISNI:0000 0001 2160 9198); Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, USA (GRID:grid.33647.35) (ISNI:0000 0001 2160 9198)
2 Syracuse University, Department of Biomedical and Chemical Engineering, Syracuse, USA (GRID:grid.264484.8) (ISNI:0000 0001 2189 1568)
3 Howard P. Isermann Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, USA (GRID:grid.33647.35) (ISNI:0000 0001 2160 9198)
4 Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, USA (GRID:grid.33647.35) (ISNI:0000 0001 2160 9198); Howard P. Isermann Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, USA (GRID:grid.33647.35) (ISNI:0000 0001 2160 9198)
5 Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, USA (GRID:grid.33647.35) (ISNI:0000 0001 2160 9198); Howard P. Isermann Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, USA (GRID:grid.33647.35) (ISNI:0000 0001 2160 9198); Rensselaer Polytechnic Institute, Department of Chemistry and Chemical Biology, Troy, USA (GRID:grid.33647.35) (ISNI:0000 0001 2160 9198); Rensselaer Polytechnic Institute, Department of Biomedical Engineering, Troy, USA (GRID:grid.33647.35) (ISNI:0000 0001 2160 9198)